

Edgar Filing: CEL SCI CORP - Form 8-K

CEL SCI CORP
Form 8-K
October 16, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): October 12, 2015

CEL-SCI CORPORATION

(Exact name of Registrant as specified in its charter)

| | | |
|---|-----------------------|--------------------------------------|
| Colorado | 01-11889 | 84-0916344 |
| ----- | ----- | ----- |
| (State or other jurisdiction of incorporation) | (Commission File No.) | (IRS Employer Identification No.) |

8229 Boone Boulevard, Suite 802
Vienna, Virginia 22182

(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (703) 506-9460

N/A

(Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below)

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-14(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement.

On October 12, 2015 the Company signed a funding agreement (the

Edgar Filing: CEL SCI CORP - Form 8-K

"Agreement") with a company established by Lake Whillans Litigation Finance, LLC, a firm specializing in funding litigation expenses. Pursuant to the Agreement, Lake Whillans Vehicle I, LLC will provide the Company with up to \$5,000,000 in funding for litigation expenses to support its \$50,000,000 arbitration claims against its former clinical research organization inVentiv Health Clinical, LLC (f/k/a PharmaNet LLC and PharmaNet GmbH (f/k/a PharmaNet AG)). The funding will be available to the Company if and when needed to fund the expenses of the ongoing arbitration and will only be repaid when the Company receives proceeds from the arbitration.

In return for providing the funding for the litigation expenses, Lake Whillans will receive:

- (i) the repayment of all funds disbursed by Lake Whillans pursuant to the Agreement;
- (ii) \$5,000,000; and
- (iii) fifteen percent (15%) of the Net Proceeds;

provided, however, that in the event the Company settles all of its claims against inVentiv on or prior to November 26, 2015, Lake Whillans will receive:

- (i) the repayment of all funds disbursed by Lake Whillans pursuant to the Agreement, plus
- (ii) the greater of 10% of the Proceeds or \$2,500,000.

For purpose of the Agreement:

"Proceeds" means all monetary awards, damages, fees, recoveries, judgements or other property or value recovered by or on behalf of the Company in connection with the arbitration.

"Net Proceeds" means the Proceeds minus the sum of (i) the funds disbursed by Lake Whillan pursuant to the Agreement, and (ii) \$5,000,000.

The foregoing summary of the Agreement is qualified in all respects to the Agreement itself which is filed as an exhibit to this report.

The hearing on the Company claims against inVentiv is scheduled to begin on March 1, 2016.

Item 9.01 Financial Statements Exhibits.

| Number | Description |
|----------|---|
| 10 (ddd) | Assignment of Proceeds and Investment Agreement |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 16, 2015

Edgar Filing: CEL SCI CORP - Form 8-K

CEL-SCI CORPORATION

By: /s/ Patricia B. Prichep

Patricia B. Prichep,
Senior Vice President of Operations